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Background and purpose   Extracorporeal shock waves (ESWs) 
are used to good effect in the treatment of soft tissue injuries, 
but the underlying mechanisms are still unknown. We therefore 
determined the effects of ESWs on normal fibroblasts in vitro, in 
order to assess treatment-induced cell response. 
Methods   A normal human fibroblast cell line (NHDF-12519) 
was treated with ESWs generated by a piezoelectric device (Piezo-
son  100;  Richard Wolfe)  using  different  protocols  of  impulses 
(300, 1,000, or 2,000 shots) and energy (0.11 or 0.22 mJ/mm2). 
Untreated controls and treated cells were cultivated for 12 days 
following a single shock-wave treatment. Viability, growth rate, 
and expression of mRNA for TGFβ-1 and collagen types I and III 
were evaluated at days 3, 6, 9, and 12.
Results      1  hour  after  shock-wave  treatment,  cell  viability 
showed a decrease related mainly to impulse numbers applied. 
Fibroblasts  treated  with  energy  of  0.22  mJ/mm2  subsequently 
showed an increase in proliferation from day 6 to day 9 that was 
higher than in untreated controls, without interference with the 
normal cell kinetic profile. mRNA expression was also higher in 
treated fibroblasts than in untreated controls for TGFβ-1 on day 
6 and day 9, for collagen type I on day 6, and for collagen type III 
on day 9.
Interpretation   These in vitro data confirm that the main fac-
tors involved in the repair process of connective tissues are acti-
vated by ESWs. The study gives the rationale for, and may pro-
vide schedules for, ESW treatment of tendonopathies.  

Fibroblasts play a crucial role in remodeling of the extracel-
lular matrix by synthesizing and organizing connective tissue 
components. These cells are responsible for the synthesis and 
assembly of ECM molecules and their typical row orienta-
tion precedes collagen fibrillogenesis (Benjamin and Ralphs 
2000). While collagen type I is the main component of col-
lagen fibers, collagen type III has been shown to be important 
in the regulation of initial fibril assembly and thus at the early 
stages of injury repair (Birk and Mayne 1997).
Fibroblasts respond to various microenvironmental signals 
including soluble cytokines and growth factors, as well as 
cell matrix or cell-cell interactions that control the balance 
between synthesis and degradation of ECM (Atamas 2002). 
Mechanotransduction, i.e. the process of converting physical 
forces into biochemical signals subsequently integrated into 
a cellular response (Iqbal and Zaidi 2005, Vogel 2006), is of 
interest because many extracorporeal therapeutic devices use 
physical  forces.  Biosynthetic  responses  to  physical  energy 
(ultrasound, electromagnetic fields) observed in vitro and in 
vivo—increase in DNA synthesis, cell proliferation, extracel-
lular matrix in bone and connective cells—Hsu and Chang 
(2004) have suggested the possibility of clinical use of this 
energy in bone and connective tissue repair.
Extracorporeal  shock  waves  (ESWs)  are  acoustic  waves 
that can induce a mechanical wave that passes through the 
cell compartment with cavitational effect; the cell response is 
proportional to the energy used (Martini et al. 2003). High-
energy shock waves have been used mainly for the treatment 
of  kidney,  gall  bladder,  or  salivary  stones,  while  recently 
many researchers have applied shock waves of lower energy 
to injured soft tissues. In spite of improvements observed in 
a number of tendonopathies, the repair mechanism involved 
in shockwave treatment is still unknown. The fact that ESWs 
enhance both bone and tendon regeneration suggests that they 
may induce some form of signal for growth and maturation of 
the mesenchymal progenitors of bone marrow.
Wang et al. (2002) have shown that ESWs induce growth 
and differentiation of bone-marrow stromal cells via TGF-β1, 
but an activity involving membrane hyperpolarization with 
Ras activation and transcription factor CBFA1 expression has 
also been shown (Wang et al. 2001). Nitric oxide has also been Acta Orthopaedica 2009; 80 (5): 612–617  613
suggested to mediate the anti-inflammatory effect of extracor-
poreal shock-wave treatment (Mariotto et al. 2005).
We explored the effects of ESWs on normal human fibro-
blasts in vitro and how the treatment can induce a cell response. 
We treated a normal fibroblast cell line in vitro with shock 
waves under different conditions of impulses and energy. After 
the treatment we evaluated fibroblast viability, the growth rate 
and pattern, and expression of mRNA for TGF-β1 and col-
lagen types I and III—the main factors involved in the repair 
process.
Material and methods
Cell line and culture 
The normal human dermal fibroblast cell line NHDF-12519 
was purchased from Cambrex Bio Science (Milan, Italy) and 
cultured in accordance with the directions of the manufac-
turer. Briefly, cells were routinely maintained in 25 cm2 flasks 
at 37°C, in 5% CO2 with 95% humidity, in fibroblast basal 
medium  (Cambrex  Bio  Science Walkersville  Inc.)  contain-
ing gentamicin and amphotericin (0.1%), insulin (0.1%) and 
hFGF-B (0.1%), and supplemented with 2% heat-inactivated 
FCS (Euroclone, Wetherby, UK). 
Exposure to shock waves
The shock-wave generator used for the in vitro experiments is 
a piezoelectric device (Piezoson 100; Richard Wolf, Knittlin-
gen, Germany) especially designed for clinical use in ortho-
pedics and traumatology. The instrument, which was kindly 
provided by Med and Sport 2000 (Torino, Italy), generates 
focused underwater shock waves at various frequencies (1–4 
shocks per second) and at various intensities (0.05–1.48 mJ/
mm2). The device comprises a high-voltage electric current 
generator and a reflector set in a water-filled container. On 
the surface of the reflector, piezoelectric elements arranged to 
form part of a sphere are stimulated with a high-energy electri-
cal pulse. This causes vibration or rapid expansion of the crys-
tals, leading to a shock wave that can be propagated through 
the water and focused at the center of the sphere. The pressure 
on the focal area is proportional to the voltage applied. The 
energy at the focal point is defined as the energy flux density 
(EFD) per impulse, recorded in joules per unit area (mJ/mm2). 
For use in orthopedics, shock waves of approximately 0.01–
0.6 mJ/mm2 are applied (Martini et al. 2003). The focal area, 
which is peculiar to each kind of generator, is defined as the 
area in which 50% of the maximum energy is reached; with 
regard to the Piezoson 100 device, it has a length of 10 mm in 
the direction of the axis of the shock wave and a diameter of 
2.5 mm perpendicular to this axis. 
Aliquots (1 mL) of cell suspension adjusted to 1 × 106 cells/
mL were placed in 2-mL polypropylene tubes (Corning, New 
York, NY), which were then completely filled with culture 
medium. Subsequently, the cells were gently pelleted by cen-
trifugation at 250 × g in order to minimize the motion during 
shock-wave treatments. The experimental set-up was as previ-
ously described (Frairia et al. 2003). Briefly, each tube con-
taining cells was placed in vertical alignment with the focal 
area and was adjusted so that the central point of the focal 
area corresponded to the center of the bottom of the tube. The 
shock wave unit was kept in contact with the tube by means 
of a water-filled cushion. Common ultrasound gel was used as 
a contact medium between cushion and tube. Different ESW 
treatment regimens were investigated: (1) an EFD of 0.11 mJ/
mm2 and peak positive pressure of 31 MPa (number of shots = 
300, 1,000, and 2,000, respectively; frequency = 4 shocks per 
second), and (2) an EFD of 0.22 mJ/mm2 and peak positive 
pressure of 90 MPa (number of shots = 300, 1,000, and 2,000, 
respectively;  frequency  =  4  shocks  per  second).  Cells  that 
received no shock-wave treatment were used as controls. The 
cell viability following the HESW treatment was determined 
with trypan blue dye exclusion. A cell viability of 50–85% has 
been considered to be effective for evaluation of the subse-
quent cell growth rate.
Hydrophone measurements showed that peak pressure and 
pressure profile were only slightly altered inside the tubes 
(data not shown).
Viability assay
After different treatment schedules, human fibroblasts from 
each tube were cultivated at a seeding concentration of 3,500 
cells per well in quadruplicate, in a 96-well plate under stan-
dard culture conditions for 12 days. On days 3, 6, 9, and 12, the 
viability of treated and untreated cells was determined with an 
assay using 3-(4,5-dimethylthiazol)-2,5 diphenyl tetrazolium 
bromide (MTT; Sigma, St Louis, MO). Briefly, 10 µL of MTT 
was added to each well. After 4 h of incubation, 100 µL of 
0.04 N NaCl in isopropanol was added and the absorbance at 
495 nm was measured using a microplate reader (Model 680; 
Bio-Rad, Hercules, CA). 
Real-time PCR for TGF-β1, collagen I and collagen III 
mRNA in normal human dermal fibroblasts
Total RNA was extracted from cells treated with ESW 0.22 
mJ/mm2 (1,000 impulses) and untreated fibroblasts (control 
group)  using  TRIzol  Reagent  (Invitrogen,  Groningen,  the 
Netherlands) following the method developed by Chomczyn-
ski and Sacchi (1987). DNase I was added to remove remain-
ing genomic DNA. 1 µg of total RNA was reverse-transcribed 
using the iScript cDNA Synthesis Kit (BioRad) following the 
manufacturer’s  protocol.  Primers  were  designed  using  the 
Beacon Designer 5.0 program according to parameters out-
lined in the BioRad iCycler Manual. The specificity of the 
primers was confirmed by Blast analysis. The collagen I gene-
specific primers used were as follows: forward 5’-TGG CAA 
AGA AGG CGG CAA AG, reverse 5’- AGC ACC AGC AGG 
ACC ATC AG. The collagen III gene-specific primers used 
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AAT GG, reverse 5’- GGG TCC TGT GTC TCC TTT GTC 
A. The TGF-β1 gene-specific primers used were as follows: 
forward 5’- ACT ACT ACG CCA AGG AGG TCA C, reverse 
5’- AGA GCA ACA CGG GTT CAG GTA.
Real-time PCR was performed using a BioRad iQ Cycler 
Detection System with SYBR green fluorophore. Reactions 
were performed in a total volume of 25 µL including 12.5 µL 
of iQ SYBR Green Supermix (BioRad), 1 µL of each primer at 
10 µM concentration, and 5 µL of the previously reverse-tran-
scribed cDNA template. The protocol for primer sets was opti-
mized using 7 serial 5× dilutions of template cDNA obtained 
from normal human dermal fibroblasts in basal condition. The 
cycling regime was as follows: denaturation (95°C for 5 min), 
followed by 40 cycles of 95°C for 15 seconds and 60°C for 1 
min. A melt-curve analysis was performed after every run to 
ensure that there was a single amplified product for every reac-
tion. All reactions were carried out at least in triplicate for every 
sample. The housekeeping gene used was that for β-actin.
Statistics
Since the aims of our experimental study were to verify how 
different ESW treatments interfere with fibroblast cell growth 
and how expression of mRNA for TGFβ-1, collagen type I 
and III, is conditioned by experiment we chose as suitable for 
our goal, we analyzed the data by a statistical test performed 
on the average for paired samples and by an extension of the 
linear model of variance analysis i.e., the Generalized Linear 
Models (Dobson 1990). This statistical model was related to 
the experimental schedule, which included repeated measures 
over the time on every sample of: cells, gene expression for 
TGFβ-1, Collagen type I and III, respectively, then considered 
as the subjects of the statistical analysis. Thus, the within- and 
between-subject  variabilities  (Davidian and  Giltinan 1995) 
were decomposed by a repeated-measures analysis of variance 
procedure. 
Assumptions  of  normality  and  sphericity  were  tested  by 
the  Kolmogorov-Smirnov  and  Mauchly  tests,  respectively. 
Levene’s test was used to test the variance equality; when 
sphericity  could  not  be  assumed,  the  Greenhouse-Geisser, 
Huynh-Feldt, and Lower-bound corrections were considered. 
The data were grouped as follows: (1) data related to differ-
ent ESW treatments; and (2) data related to TGF-β1, collagen 
type I and collagen type III gene expression: the variables con-
sidered were treatment and interaction time/treatment.
Within- and between-subjects effects were considered sig-
nificant with p-values less than 0.05. The statistical analyses 
were done using SPSS 13.0 for Windows.
Results
Cell viability
1  hour  after  the  shock-wave  treatment,  the  cell  viability 
showed an apparent decrease related both to the energy and the 
number of impulses applied: a constant decrease was observed 
in relation to the number of impulses (300, 1,000, 2,000) with 
a maximum reduction in viability at 2,000 impulses (viability 
18%) while there was no statistically significant association 
between energy levels (0.11 and 0.22 mJ/mm2) and fibroblast 
viability (Figure 1). 
Cell growth pattern
Fibroblasts treated with ESW (energy = 0.22 mJ/mm2; 1,000 
and  2,000  impulses)  showed  a  significant  increase  in  cell 
growth relative to the controls (p < 0.001). A critical increase 
in cell growth was observed from the sixth to the twelvth day of 
the proliferation curve (Figure 2). No change was observed in 
the pattern of the growth curve either in treated or in untreated 
cells (p > 0.05). Since the goal of ESW treatment of tendon 
lesions is to promote and improve the repair process, treat-
ment at the 0.22 mJ/mm2 energy level with 1,000 impulses 
appears to be the condition in which fibroblast viability fits 
growth dynamics. 
RNA expression
The  pattern  of  expression  of  TGF-β1  mRNA  was  similar 
in ESW-treated and untreated fibroblasts over the period of 
observation. A decrease in expression was observed in both 
groups from the third to the sixth day (p < 0.001). The follow-
ing increase showed higher values in treated fibroblasts than 
in untreated fibroblasts for the sixth (p = 0.02) and ninth days 
(p = 0.02), respectively (Figure 3).
mRNA expression for collagen types I and III showed a dif-
ferent pattern in the untreated and treated groups (p < 0.001): 
mRNA expression for collagen type I showed a rapid fall in 
treated fibroblasts relative to the controls (p < 0.001) on the 
third day of culture and increased again on the following days, 
with levels higher in treated cells than in untreated cells from 
the sixth to the twelvth day (p < 0.001) (Figure 4). mRNA 
expression for collagen type III, after the fall on the third day 
(p < 0.001), was higher in treated fibroblasts than in untreated 
fibroblasts  on  the  ninth  and  the  twelvth  days  (p < 0.001) 
(Figure 5). 
ESW treatment was associated with an increase in mRNA 
expression for collagen type I on the sixth day, and anticipated 
the mRNA expression for collagen type III on the ninth day 
with respect to the controls (Figure 6). 
We compared expression of mRNA for TGF-β1 with the 
fibroblast growth curve, and similarly mRNA expression for 
collagen type I and collagen type III, both in untreated and 
treated cells. The treatment interfered with the behavior of 
mRNA expression for TGF-β1 versus the other factors con-
sidered. The difference between the curves of TGF-β1 mRNA 
and collagen I mRNA expression in ESW-treated fibroblasts 
relative to the controls was higher than in all other conditions 
(linear, p < 0.001: squared, p = 0.005, cubic, p < 0.001). Table 
I further confirms how the intra-subject variability was condi-
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Discussion 
We found that shock waves had a dose-depen-
dent destructive effect on cells in suspension, 
but they also seemed to have a dose-depen-
dent stimulatory effect on cell proliferation. 
We  chose  to  treat  fibroblasts  in  suspension 
with  low-  to  medium-energy  shock  waves; 
this  induced  fewer  immediate  cytodestruc-
tive effects and there was a better subsequent 
stimulation  of  cell  proliferation,  in  accor-
Figure 1. Effect of ESW treatment on cell via-
bility. Viability is expressed as ratio between 
cells treated with shock waves and untreated 
controls (n = 16). a p < 0.05; b p < 0.001 relative 
to untreated controls.
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Figure  2.  Effect  of  ESW  treatment  on  cell 
growth.  Cell  growth  was  determined  by  the 
MTT method. Day 0 was seeding day (n = 16).
Figure 3. Effect of ESW treatment on TGF-β1 
expression. Relative expression of TGF-β1 
after treatment with ESW (EFD = 0.22 mJ/
mm2, 1,000 impulses) (n = 4). Significance 
compared to no treatment: a p < 0.05.
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Figure 4. Effect of ESW treatment on collagen 
type I expression. Relative expression of col-
lagen type I after treatment with ESW (EFD = 
0.22mJ/mm2, 1,000 impulses) (n = 4). Signifi-
cance compared to no treatment: b p < 0.001.
Figure 5. Effect of ESW treatment on collagen 
type III expression. Relative expression of col-
lagen type III after treatment with ESW (EFD = 
0.22mJ/mm2, 1,000 impulses) (n = 4). Signifi-
cance compared to no treatment: b p < 0.001.
Figure 6. Effect on collagen type I/colla-
gen type III ratio after treatment with ESW 
(EFD = 0.22mJ/mm2, 1,000 impulses) (n 
= 4). 
Mean values (SD) of cell growth (from absorbance) and relative expression of TGF-
β1, collagen type I and collagen type III after treatment with ESW
Day   Treatment   Cell growth  TGFβ	 Collagen I  Collagen III
    (n = 16)   (n = 4)   (n = 4)  (n = 4)
  3  No treatment   0.06 (0.004)    3.61 (0.28)   4.14 (0.37)   3.98 (0.54) 
  HESW   0.13 (0.003)    2.71 (0.041)   1.15 (0.17)   1.22 (0.26)
  6  No treatment    0.15 (0.031)    1.05 (0.13)   2.44 (0.017)   1.64 (0.075) 
  HESW    0.24 (0.036)    1.94 (0.052)   2.81 (0.061)   1.53 (0.051)
  9  No treatment    0.26 (0.073)    2.60 (0.027)   2.04 (0.043)   1.67 (0.058) 
  HESW    0.32 (0.036)    3.50 (0.048)   2.69 (0.031)   2.67 (0.16)
12  No treatment   0.19 (0.044)    3.17 (0.033)   2.32 (0.034)   2.75 (0.24) 
  HESW   0.25 (0.030)    3.49 (0.027)    4.33 (0.039)   3.91 (0.10)616  Acta Orthopaedica 2009; 80 (5): 612–617
dance with the work of Wang et al. (2001, 2002) and Martini 
et al. (2003). Our data indicate that a limited number of shock 
waves can produce minor damage in soft tissue, favoring the 
healing process; fibroblast proliferation is one of the main 
factors and is the first step. Fibroblasts interact with the extra-
cellular matrix and they are influenced by systemic factors 
related or unrelated to inflammation. Such factors include 
ischemia, serotonin, endothelin, thrombin, leptin and others 
(Atamas 2002). Biochemical signals are mediators of the con-
version of physical forces into biological activity, and fibro-
blasts have been shown to be mechanosensitive cells (Iqbal 
and Zaidi 2005). The proliferative response we observed in 
treated  fibroblasts  confirms  that  ESW  treatment  imparts  a 
normal mitogenic stimulus.
Many different kinds of cells synthesize TGF-β1, which 
acts by both autocrine and paracrine mechanisms. It can either 
stimulate or inhibit proliferation, and either stimulate or inhibit 
differentiation, thus playing an important role in connective 
tissue as well as in the healing process, including tendon repair 
(Atamas 2002). Our findings show that the shock-wave treat-
ment enhances expression of mRNA for TGF-β1 and does not 
interfere with the normal physiological pattern of expression, 
over the proliferation curve. The observed decrease in mRNA 
expression for TGF-β1 on the third day of culture both in 
untreated and treated fibroblasts is consistent with the injury 
involved in the transfer of cells onto the wells of the plates and, 
in treated fibroblasts, even with the ESW treatment, according 
to the findings of Dahlgreen et al. (2005). The rapid increase 
both in fibroblast proliferation and in expression of TGF-β1 
mRNA is consistent with a strong healing response.
The cavitation effect induced by ESWs results in immedi-
ate and long-lasting events at the cellular level, from changes 
in membrane potential to activation of molecular autocrine 
and paracrine signals induced by mechanotransduction. The 
mechanical force of shock waves has been hypothesized to 
serve as extracellular information that is transmitted to cells 
and modulates the expression of genes that regulate the growth, 
function, and differentiation of cells (Chao et al. 2008).
We also found elevated expression of mRNA for collagen 
types I and III, although with different timing: on the sixth 
day for collagen type I and on the ninth day for collagen type 
III. In both cases, ESW treatment enhances expression of the 
genes encoding collagen types I and III, which is in accor-
dance with the results of other authors who studied human 
fibroblasts exposed to electromagnetic fields (Rodemann et al. 
1989).
The central event in the architecture of tendons is collagen 
fibrillogenesis (Dahlgreen et al. 2005) and both collagen types 
I and III have been shown to be key players in the regulation 
of fibril assembly, which follows the typical row orientation of 
tendon fibroblasts.
Our  data  confirm  that  ESW  treatment  promotes  and 
improves  the  repair  process  through  accelerated  timing  of 
RNA expression for TGF-β1, collagen I and collagen III (rela-
tive to untreated fibroblasts). The results, in line with previ-
ous reports using a rat model (Orhan et al. 2004) and a rabbit 
model (Wang et al. 2008) and also on human tendon ailments 
(Rompe et al. 2007, 2008), support the efficacy of clinical 
application of ESW in different types of tendonopathies and 
tendon injuries. 
Since  shock-wave  treatment  circumvents  the  need  for 
immobilization and for reduced weight bearing (Rompe et 
al. 2008), it allows—in most cases—a graduated and precise 
load, favoring the normal remodeling process. Clinical studies 
have shown the benefit of early mobilization following tendon 
repair, and several postoperative mobilization protocols have 
been advocated, as reviewed by Sharma and Maffulli (2005), 
even if the precise mechanism by which cells respond to load 
remains to be elucidated. The clinical observations are in accor-
dance with the report by Chen et al. (2004) using a rat model, 
who described how the increased fibroblast proliferation and 
biosynthesis of ECM and collagens, as well as the mechanical 
stress, are crucial for return to normal tendon strength. Most 
recently, Chao et al (2008) showed that shock waves applied 
to tenocytes harvested from Spague-Dawley rats can stimulate 
tenocyte proliferation, which is mediated by early upregulation 
of proliferating cell nuclear antigen (PCNA) and TGF-β1 gene 
expression, endogenous NO release, and then TGF-β1 protein 
and collagen synthesis. The authors hypothesized that shock 
waves could act as extracellular information that is transmit-
ted to cells, thereby modulating the expression of genes that 
regulate cell growth, function, and differentiation.
The data from comparison between expression of TGF-β1 
mRNA and cell proliferation, and mRNA expression for col-
lagen types I and III suggest that TGF-β1 plays a role in fibro-
blast growth, which is in accordance with previous publica-
tions (Chen et al. 2004, Chao et al. 2008) reporting that ESW 
increases tenocyte proliferation via TGF-β1. The timing of the 
increase in mRNA expression for collagen I and collagen III 
we observed after ESW exposure may also be related to TGF-
β1 activation. The differences found in the behavior of TGF-
β1 and collagen I mRNA expression in untreated and treated 
fibroblasts even suggest that different mechanisms may be 
involved, as suggested by Aaron et al. (2004). 
We  conclude  that  ESW  treatment  applied  to  fibroblasts 
in vitro enhances cell proliferation and induces changes in 
mRNA expression for TGF-β1, collagen I and collagen III that 
are consistent with activation and acceleration of the healing 
process. Although the experiments in vitro cannot be directly 
extrapolated to the in vivo situation, the differences in viability 
and proliferation rate observed in fibroblasts treated in vitro 
with different energy and impulse regimes may provide useful 
information for schedules of ESW treatment in vivo.
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